帝人 announced that it will return the manufacturing and marketing licenses for 2 pharmaceutical products to the licensors in January 2027. It plans to change the exclusive domestic licenses to 日本ケミファ and アルフレッサファーマ and focus resources in its pharmaceutical business on rare diseases.
帝人 formally announced that it will return the manufacturing and marketing rights for 2 pharmaceutical products to the licensors in January 2027. This is a measure associated with the expiry of the license term.
As the transferees, the expectorant Mucosolvan will change from 帝人ファーマ to 日本ケミファ, while the constipation treatment Laxoberon Oral Solution 0.75% will change from 帝人ファーマ to アルフレッサファーマ. Both will become the domestic licensors.
帝人 has set out a medium-term management plan through the fiscal year ending March 2029 that focuses management resources in its pharmaceutical business on rare diseases, and in June 2026 announced the sale of 7 products, including the gout treatment Feburic.
帝人ファーマ held the exclusive domestic license. Going forward, the strategy is expected to concentrate business resources in the rare-disease field in light of the license return and transfer.